MedTrace Logo

Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

NCT01024140 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-12-02

No results posted yet for this study

Summary

The primary aim of this pilot study is to test the efficacy of the selective serotonin re-uptake inhibitor, Escitalopram, in the treatment of posttraumatic stress disorder (PTSD) in an open clinical trial.

A secondary aim is to determine whether treatment with escitalopram increases plasma allopregnanolone levels in patients with PTSD and if increases in allopregnanolone levels are correlated with treatment efficacy.

Conditions

  • Chronic Posttraumatic Stress Disorder

Interventions

DRUG

Escitalopram

Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.

Sponsors & Collaborators

  • Northern California Institute of Research and Education

    lead OTHER

Principal Investigators

  • Thomas C Neylan, MD · UCSF / VAMC / NCIRE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2004-12-31
Completion
2004-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01024140 on ClinicalTrials.gov